Pharmaceutical conglomerate Pfizer acquired US-based biopharmaceutical company Excaliard yesterday for an undisclosed amount yesterday in a transaction expected to close before the end of the year. Excaliard’s only significant financing since its 2006 founding was a $15.5m series A round in November 2007, by biomedical company Isis Pharmaceuticals and venture capital firms Alta Partners, ProQuest…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
